<DOC>
	<DOCNO>NCT02008318</DOCNO>
	<brief_summary>The purpose study investigate effect study drug know LY2157299 red blood cell participant myelodysplastic syndrome ( MDS ) . Participants different degree disease ( low , low , intermediate risk ) study . The study treatment expect last 6 month participant .</brief_summary>
	<brief_title>A Study LY2157299 Participants With Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Confirmed diagnosis MDS base World Health Organization ( WHO ) criteria Participants 5q deletion allow fail intolerant lenalidomide treatment Participants must Revised International Prognostic Scoring System ( IPSSR ) category low , low , intermediaterisk disease In 8 week prior registration , participant phase 2 anemia Hb ≤10.0 g/dL ( base average 2 baseline measurement untransfused least 1 week ) without red blood cell ( RBC ) transfusion dependence confirm minimum 8 week enrollment For phase 3 , participant anemia RBC transfusion dependence confirm within 8 week enrollment Performance status ≤2 Eastern Cooperative Oncology Group ( ECOG ) scale No history moderate severe cardiac disease No prior history acute myeloid leukemia ( AML )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>